Rangering i aksjer
#35164
Gamida Cell Ltd. operates as a clinical-stage biopharmaceutical firm, dedicated... Gamida Cell Ltd. operates as a clinical-stage biopharmaceutical firm, dedicated to pioneering cell therapies aimed at eradicating blood cancers and other severe hematological conditions. The company's leading investigational product, omidubicel—a specialized cell therapy—has successfully concluded its Phase III clinical evaluation for individuals afflicted with high-risk hematologic malignancies. Furthermore, it is currently undergoing Phase I/II trials for patients suffering from severe aplastic anemia. Another significant therapeutic candidate, GDA-201, an immunotherapy harnessing natural killer cells, is progressing through Phase I/II studies to address relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. Beyond these, Gamida Cell is actively advancing a broader natural killer (NK) cell pipeline, which includes GDA-301, GDA-401, GDA-501, and GDA-601, with the ambition of treating both hematologic cancers and solid tumors. Founded in 1998, the company maintains its corporate headquarters in Jerusalem, Israel.
Aksjekurs
$0.0327
Sist synkronisert: 2025-06-17
Handel Gamida Cell Ltd. (GMDA)
Pris GMDA pris med markedsverdi på B
Markedsverdi av Gamida Cell Ltd.(GMDA)
Markedsverdi: $4.34M
Per August 2026 har Gamida Cell Ltd. en markedsverdi på $4.34M. Dette gjør Gamida Cell Ltd. til det 35164th mest verdifulle selskapet i verden basert på markedsverdi ifølge våre data. Markedsverdi er den totale markedsverdien av et børsnotert selskaps utestående aksjer og brukes vanligvis til å måle hvor mye et selskap er verdt.
Markedsverdihistorikk for Gamida Cell Ltd. fra 2018 til 2026
GMDA sammenlignet med topp 5 mest populære stocks
| Pris på GMDA |
|
Eiendel B |
Markedsverdi for B |
Resultater |
|
|
|
|
$5.452T
|
+125,692,588.97%
|
|
|
|
|
$4.490T
|
+103,517,214.83%
|
|
|
|
|
$4.162T
|
+95,964,100.96%
|
|
|
|
|
$3.676T
|
+84,757,892.92%
|
|
|
|
|
$2.833T
|
+65,315,634.53%
|
